Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same author

Clinical outcomes and remission trajectories in obese and non-obese patients with severe asthma treated with biologics: a retrospective longitudinal cohort study from the Severe Asthma Network Italy (SANI) registry.

The Lancet regional health. Europe·2026
Same author

Real-world applicability of steatotic liver disease nomenclature: multifactorial phenotypes as an unmet classification need.

Internal and emergency medicine·2026
Same author

Chlamydia trachomatis proctitis mimicking an inflammatory bowel disease and hiding human immunodeficiency virus infection.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same author

Insulin Growth Factor Binding Protein-6 and the Liver.

Cells·2026
Same author

Ultramicronized palmitoylethanolamide restores astrocyte-neuron metabolic coupling and Klotho/FGF21 signaling in a triple-transgenic mouse model of Alzheimer's disease.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Related Experiment Video

Updated: Jun 2, 2026

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

Mitochondrial dysfunction in nonalcoholic steatohepatitis.

Gaetano Serviddio1, Francesco Bellanti, Gianluigi Vendemiale

  • 1CURE (Centre for Liver Disease Research and Treatment), Department of Medical and Occupational Sciences, University of Foggia, 70124 Foggia, Italy. g.serviddio@unifg.it

Expert Review of Gastroenterology & Hepatology
|April 12, 2011
PubMed
Summary
This summary is machine-generated.

Mitochondrial dysfunction drives nonalcoholic steatohepatitis (NASH) by disrupting fat metabolism and increasing oxidative stress. Targeting mitochondria may offer new therapeutic strategies for NASH progression.

More Related Videos

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Related Experiment Videos

Last Updated: Jun 2, 2026

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Area of Science:

  • Hepatology
  • Mitochondrial Biology
  • Cellular Metabolism

Background:

  • Nonalcoholic steatohepatitis (NASH) pathogenesis is complex and not fully understood.
  • Mitochondrial dysfunction is implicated in NASH, affecting liver homeostasis and promoting cell damage.
  • Key mechanisms involve impaired fat metabolism, energy imbalance, and oxidative stress.

Purpose of the Study:

  • To review the role of mitochondria in NASH pathogenesis.
  • To focus on mitochondrial impairment and uncoupling proteins in NASH progression.
  • To discuss potential mitochondrial-targeted therapies for NASH.

Main Methods:

  • Literature review of mitochondrial roles in NASH.
  • Analysis of fat metabolism and energy homeostasis pathways.
  • Examination of reactive oxygen species (ROS) production and lipid peroxidation.

Main Results:

  • Mitochondrial dysfunction impairs fatty liver homeostasis.
  • Overproduction of free radicals by mitochondria triggers lipid peroxidation and cell death.
  • Mitochondrial uncoupling proteins play a role in NASH pathophysiology.

Conclusions:

  • Mitochondria are central to NASH development and progression.
  • Mitochondrial impairment exacerbates NASH.
  • Mitochondria-targeted molecules show therapeutic potential for NASH.